drugset / Trial / NCT00451646

Study Comparing the Safety and Tolerance of SMOFlipid 20% in Long-term Treatment With Parenteral Nutrition

NCT00451646

Phase 3 Completed 75 enrolled Fresenius Kabi
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of this study is to evaluate the safety and tolerance of SMOFlipid 20% in comparison to a standard lipid emulsion Intralipid 20% in patients requiring long-term parenteral nutrition. The safety and tolerance will be evaluated by biochemistry, hematology and coagulation variables, vital signs and adverse events. Further objectives to evaluate are the influence of SMOFlipid 20% on inflammation processes, the efficacy of anti-oxidative properties of vitamin E supplemented to SMOFlipid 20%, and the fatty acid pattern in red blood cells and serum.

Timeline

Start
2007-10
Primary completion
2008-10
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Intralipid Other / unclassified 1 g
Subject Intralipid Other / unclassified 2 g
Subject SMOFlipid Other / unclassified 1 g
Subject SMOFlipid Other / unclassified 2 g

Indications

No indication recorded.